Details for Patent: 8,058,467

« Back to Dashboard

Which drugs does patent 8,058,467 protect, and when does it expire?

Patent 8,058,467 protects VYZULTA and is included in one NDA.

This patent has fifty-three patent family members in thirty-eight countries.

Summary for Patent: 8,058,467

Title:	Prostaglandin derivatives
Abstract:	Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
Inventor(s):	Ennio Ongini, Valerio Chiroli, Francesca Benedini, Piero Del Soldato
Assignee:	Nicox SA
Application Number:	US13/025,740
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,058,467
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,058,467

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch And Lomb	VYZULTA	latanoprostene bunod	SOLUTION/DROPS;OPHTHALMIC	207795-001	Nov 2, 2017	AB	RX	Yes	Yes				Y		REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Foreign Priority and PCT Information for Patent: 8,058,467

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	04100001	Jan 5, 2004

International Family Members for US Patent 8,058,467

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	047081
Argentina	098931
Australia	2004313688
Brazil	PI0418245
Canada	2551409
China	100469765
China	1906159